(d) Seropositivity in off\treatment patients with RCC and patients with RCC receiving therapy with ICIs??TKIs or TKIs only

(d) Seropositivity in off\treatment patients with RCC and patients with RCC receiving therapy with ICIs??TKIs or TKIs only. and 40 with ICI therapy. In the UC and RCC groups, 37 of 57 (65%) and 21 of 28 (75%) patients, respectively, were actively undergoing anticancer therapy, and the remainder in both groups were off treatment. Steroids were administrated to nine patients for immune\related AEs and the dose of steroids was 10?mg or less at the time of vaccination. Table D-Luciferin 1 Background of participants RCC. A cross\sectional representation of anti\SARS\CoV\2 S IgG antibody titers is usually shown in Physique?1. After the second BNT162b2 vaccination dose, all participants (100%) in the Ctrl group and 78 of 85 (92%) patients with UC or RCC were seropositive for SARS\CoV\2?S IgG antibodies. The anti\SARS\CoV\2?S IgG antibody titer was not significantly different between the UC (median 431?U/mL) and RCC groups (median 500?U/mL) (P?=?0.334, Fig.?2a). D-Luciferin The seropositivity rate in the UC, and RCC groups was 90%, and 96%, respectively (P?=?0.417, Fig.?2b). The anti\SARS\CoV\2?S IgG antibody titer did not significantly differ between patients with nonmetastatic disease (M0; median 458?U/mL) and metastatic disease (M1; median 427?U/mL) (P?=?0.319, Fig.?2c). The seropositivity rate in the patients with stage M0 and M1 disease was 97% and 89%, respectively (P?=?0.413, Fig.?2d). Open in a separate windows Fig. 1 Cross\sectional evaluation of anti\SARS\CoV\2 IgG S antibody titers. Plot of the anti\SARS\CoV\2 IgG S antibody titers after the first BNT162b2 vaccine dose. Seropositivity was defined as 15?U/mL, which was considered to indicate the presence of neutralizing antibodies. [Colour figure can be viewed at wileyonlinelibrary.com] Open in a separate window Fig. 2 Comparison of anti\SARS\CoV\2 IgG S antibody titers and seropositivity among the Ctrl, UC, and RCC groups. (a) Comparison of antibody D-Luciferin titers between patients with UC and RCC. (b) Seropositivity in patients with UC, and patients with RCC. (c) Comparison of antibody titers between patients with nonmetastatic (M0) and metastatic (M1) disease. (d) Seropositivity in patients with M0 and M1 disease. [Colour figure can be viewed at wileyonlinelibrary.com] We observed that 92% (n?=?53/58) of patients undergoing active anticancer therapy were seropositive. The seropositivity rate among the patients with active anticancer therapy in the UC and RCC groups was 87% (n?=?33/37) and 95% (n?=?20/21), respectively. In the UC group, the anti\SARS\CoV\2?S IgG antibody titer did not significantly differ between the off\treatment patients (median 458?U/mL) and those receiving ICI therapy (median 369?U/mL) and between the off\treatment patients and those receiving systemic chemotherapy (median 779?U/mL) (Fig.?3a). The seropositivity rate in patients with UC in the ICI therapy, chemotherapy, and off\treatment groups was 87%, 86%, and 95%, respectively (Fig.?3b). In the RCC group, the anti\SARS\CoV\2?S IgG antibody titer did not significantly differ between the off\treatment patients (median 927?U/mL) and those receiving therapy with ICIs??TKIs (median 369?U/mL) and between the off\treatment patients and those receiving TKIs (median 516?U/mL) (Fig.?3c). The seropositivity rate in patients with UC in the ICIs??TKI therapy, TKI therapy, and off\treatment groups was 100%, 91%, and 100%, respectively (Fig.?3d). The anti\SARS\CoV\2?S antibody titer in patients with concomitant steroid use (median 72?U/mL) was significantly lower than those without concomitant steroid use (median 480?U/mL) (P?=?0.014, Fig.?3e). The seropositivity rate in patients with steroids (?) and steroids (+) was 92% and 89%, respectively (P?=?0.557, Fig.?3f). The seropositivity rate in patients with concomitant steroid use in the UC and RCC groups was 89% and 96%, respectively (Fig.?3f). We evaluated the effect of prior therapy on anti\SARS\CoV\2?S IgG antibody titer in UC patients who are treated with ICI (n?=?30) (Fig.?S1a). The seropositivity in patients with ICI 2 lines (n?=?28) and 3 lines (n?=?2) was 89% and 50%, respectively (Fig.?S1b). We observed no significant association between the time anti\SARS\CoV\2?S IgG antibody titer and time Rabbit Polyclonal to PCNA from final administration of chemotherapy to initiation of ICIs therapy (Fig.?S1), time from final administration of chemotherapy.